stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Varian Medical Systems, Inc.

United States · NYSE: VAR · Market cap: · P/E: · P/S:

Varian makes radiation therapy and proton therapy machines and software that cancer treatment centers use to treat patients.

Varian builds the machines and software that cancer doctors use to aim powerful beams of radiation at tumors. When a patient needs radiation therapy, the treatment is usually delivered by a linear accelerator — a big machine that rotates around the patient and fires precise doses of energy at the cancer while trying to spare the healthy tissue nearby. Varian is one of the biggest makers of those machines, and it also sells the software that hospitals use to plan treatments, run the machines, and keep track of patient data. Cancer centers buy this equipment and software directly, and they choose Varian because the hardware, software, and service all fit together and the brand is trusted in clinics around the world.

The company also has a second, more specialized business: proton therapy. Proton therapy is a different way of delivering radiation that uses protons instead of X-rays and can be aimed to stop at a precise depth in the body, which can be gentler on surrounding tissue. Proton therapy systems are enormous, cost hundreds of millions of dollars, and are sold to large hospitals and research centers. That makes this a lumpy business — a single sale can be huge, but there aren't many buyers, and projects can take years to build out. Varian's mainstay, though, is the more common radiation therapy equipment, where it is a leading player alongside competitors like Elekta and Siemens Healthineers. What makes the business strong is that it is not just a one-time machine sale. Varian earns money from servicing and upgrading machines, licensing software, and selling replacement parts, which creates a steadier stream of revenue on top of the big equipment orders. Hospitals tend to stick with a vendor once they've built their workflows around it, because swapping out treatment machines and software is expensive and disruptive. That switching cost gives Varian real staying power, and it helps explain why the company built a large installed base over decades. The company was founded in 1948 and grew out of work connected to Stanford, eventually becoming the dominant name in radiation therapy equipment. One important turning point came in 2020, when Siemens Healthineers agreed to acquire Varian in a deal valued at roughly $16 billion, folding the radiation therapy leader into a larger medical technology group. Before that deal closed in 2021, Varian traded on the New York Stock Exchange under its own ticker. Its business sits at the intersection of cancer care and expensive capital equipment, which means demand depends on hospitals having budgets and on the pace of new cancer treatment capacity being built around the world.


The honest risk is that this is a mature, capital-intensive business with a limited pool of buyers. Big equipment orders can rise and fall with hospital spending, and proton therapy has been slower to spread than some hoped because of its cost and complexity. Still, cancer isn't going away, and radiation therapy remains a core treatment for many patients. Varian's position as a leading supplier of the machines and software that deliver that treatment gives it a durable role in a market that grows as cancer care expands globally.

Saved answer · last researched 15 Nov 2026